Proficio Capital Partners LLC Acquires 1,562 Shares of Eli Lilly and Company (NYSE:LLY)
Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 30.2% in the fourth ...
Eli Lilly and Company (NYSE:LLY) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...
Medscape2d
CAC Scans, Statins, and Coaching Can Lower Plaque Volume. Does It Matter?
People with intermediate-risk scores on coronary artery calcium testing who received statins and intensive health coaching ...
The American Journal of Managed Care2d
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...
Indianapolis Business Journal2d
Q&A with the head of Lilly manufacturing, who meticulously tracks gains in work, life
"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...
Council on Foreign Relations2d
American Pharmaceutical Companies Still Aren’t Paying Tax in the U.S.
K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.
Healio2d
Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...
How Much Should Weight Loss Drugs Cost?
A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...
The drugstore industry is struggling. Here's what could be in its future.
But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...
ProQR Therapeutics N.V.: ProQR Announces Year End 2024 Operating and Financial Results
Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Diabetes drug price war heats up, making treatment more affordable
Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...